Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVOCART 3D plus versus microfracture for knee articular cartilage defects
NL-OMON40824Phase 3Withdrawn
- Sponsor
- TETEC AG
- Start
- Jul 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of NOVOCART 3D in cartilage defect of knee and Cartilage Injury of the Knee (2 arms), sponsored by TETEC AG. Planned start Jul 2014; status: withdrawn.
02
Drugs
NOVOCART 3D
03
Conditions
cartilage defect of kneeCartilage Injury of the Knee
Beyond the preview
Go deeper on NL-OMON40824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40824.